from our ceo company leadership company leadership management team board of directors partnering with acorda grant program scientific award contact us compliance for patients for patients focus on therapies in the community assistance programs resources products & research products & research pipeline arcus technology products products ampyra dalfampridine zanaflex capsules tizanidine hcl qutenza capsaicin 8 % patch clinical trials research & development research & development cvt 301 dalfampridine cvt 427 rhigm22 investors investors corporate governance stock information investor events investor news financial information financial information quarterly reports annual reports sec filings analysts investor resources investor resources investor kit e mail alerts faqs ir contact biotie therapies tender offer news & events news & events in the news awards press releases company events social media careers careers working at acorda our employees benefits job openings internship program application privacy policy terms of use site map contact us investors acorda therapeutics inc. is a biotechnology company whose mission is to develop and market therapies ... learn more for patients we founded acorda to bring life changing therapies to people living with a wide range of nervous system disorders ... learn more careers we look for talented motivated people who want to make a difference in people s lives ... learn more leahampyra patient since 2010 learn about ampyra susanampyra patient since 2010 learn about ampyra about acorda the one thing you should know about acorda therapeutics is that everything we do is aimed at improving the lives of millions of people with nervous system disorders ... learn more products & research we have a deep understanding and experience in nervous systems research product development and commercialization ... learn more fredampyra patient since 2010 learn about ampyra news & events acorda maintains open dialogue with patients caregivers healthcare professionals and investors ... learn more thursday october 13 2016 data from clinical and preclinical trials of cvt 301 for treatment of off periods in parkinsons disease published in science translational medicine more news one of the nation s best workplaces recognized among best workplaces for women 2 years in a row acorda scientific excellence award voted among best places to work every year since 2011 my parents always told me that you should do in life what you love . there s no point in doing something in your life that you don t. and that s what i get to do here see the video see the video about acorda message from our ceo company leadership management team board of directors partnering with acorda grant program scientific award contact us compliance for patients focus on therapies in the community assistance programs resources products & research pipeline arcus technology products ampyra dalfampridine zanaflex capsules tizanidine hcl qutenza capsaicin 8 % patch clinical trials research & development cvt 301 dalfampridine cvt 427 rhigm22 investors corporate governance stock information investor events investor news financial information quarterly reports annual reports sec filings analysts investor resources investor kit e mail alerts faqs ir contact biotie therapies tender offer news & events in the news awards press releases company events social media careers working at acorda our employees benefits job openings internship program application privacy policy terms of use site map contact us alert close ... you are now leaving the acorda.com site . by clicking ok you will be leaving this website sponsored by acorda therapeutics inc. to enter an external and entirely independent website . acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites . ok cancel close ... acorda named one of 100 best workplaces for women 2015 click for more information